ParkinsonFranceV1, PascalFrancis, Corpus, bibRecord, 000E47

Clinical pharmacology of MAO inhibitors: Safety and future

Identifieur interne : 000E47 ( PascalFrancis/Corpus ); précédent : 000E46; suivant : 000E48

Clinical pharmacology of MAO inhibitors: Safety and future

Auteurs : Mitsuhiko Yamada ; Hajime Yasuhara

Source :

Neurotoxicology : (Park Forest South) [ 0161-813X ] ; 2004.

RBID : Pascal:04-0190285

Descripteurs français

Pascal (Inist)
- Pharmacologie clinique, IMAO, Toxicité, Neurologie, Toxicologie.

English descriptors

KwdEn :
- Clinical pharmacology, MAO inhibitor, Neurology, Toxicity, Toxicology.

Abstract

In this article, we review the clinical pharmacology of monoamine oxidase inhibitors (MAOIs). Now, MAOIs are used for the treatment of depressive disorders, anxiety disorders, Parkinson's disease, and Alzheimer's disease. The selective monoamine oxidase-B inhibitor selegiline and the selective and reversible inhibitor of monoamine oxidase-A (RIMA) moclobemide are free from the hypertensive crisis, the so-called cheese effect. Therefore, selective MAO-B inhibitors and RIMAs hold promise as safer alternatives to classical MAOIs. It is clear that much remains to be investigated with regard to the clinical pharmacology of MAOIs. It seems obvious that a greater understanding of the pharmacodynamics and pharmacokinetics of MAOIs could result in improved treatment of the patients in the future.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0161-813X`
A03		`1`		`@0 Neurotoxicology : (Park Forest South)`
A05				`@2 25`
A06				`@2 1-2`
A08	`01`	`1`	`ENG`	`@1 Clinical pharmacology of MAO inhibitors: Safety and future`
A09	`01`	`1`	`ENG`	`@1 Monoamine Oxidases: Molecular, Pharmacological and Neurotoxicological Aspects. A Tribute to Prof. Merton Sandler`
A11	`01`	`1`		`@1 YAMADA (Mitsuhiko)`
A11	`02`	`1`		`@1 YASUHARA (Hajime)`
A12	`01`	`1`		`@1 NICOTRA (A.) @9 ed.`
A12	`02`	`1`		`@1 PARVEZ (S. H.) @9 ed.`
A12	`03`	`1`		`@1 GLOVER (V.) @9 ed.`
A12	`04`	`1`		`@1 SANDLER (M.) @9 ed.`
A12	`05`	`1`		`@1 PARVEZ (S.) @9 ed.`
A12	`06`	`1`		`@1 MINAMI (M.) @9 ed.`
A14	`01`			`@1 Department of Psychiatry, Showa University Karasuyama Hospital, 6-11-11 Kitakarasuyama @2 Setagaya, Tokyo 157-8577 @3 JPN @Z 1 aut.`
A14	`02`			`@1 Department of Pharmacology, Showa University School of Medicine @2 Tokyo 142-8555 @3 JPN @Z 2 aut.`
A15	`01`			`@1 Dept. Animal and Human Biology, University of Rome I, Viale dell'Università 32 @2 00198 Rome @3 ITA @Z 1 aut.`
A15	`02`			`@1 Institut Alfred Fressard of Neuroscience, Bât5 Parc Chateau, CNRS @2 91190 Gif sur Yvette @3 FRA @Z 2 aut. @Z 5 aut.`
A15	`03`			`@1 Institute of Reproductive and Developmental Biology, Imperial College London, Hammersmith Campus, Du Cane Road @2 London, W12 ONN @3 GBR @Z 3 aut. @Z 4 aut.`
A15	`04`			`@1 The Research Institute of Personalized Health, Health Sciences University of Hokkaido @2 061-0293 Ishikari-Tobetsu @3 JPN @Z 6 aut.`
A20				`@1 215-221`
A21				`@1 2004`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 18397 @5 354000119285470220`
A44				`@0 0000 @1 © 2004 INIST-CNRS. All rights reserved.`
A45				`@0 1 p.1/4`
A47	`01`	`1`		`@0 04-0190285`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Neurotoxicology : (Park Forest South)`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 In this article, we review the clinical pharmacology of monoamine oxidase inhibitors (MAOIs). Now, MAOIs are used for the treatment of depressive disorders, anxiety disorders, Parkinson's disease, and Alzheimer's disease. The selective monoamine oxidase-B inhibitor selegiline and the selective and reversible inhibitor of monoamine oxidase-A (RIMA) moclobemide are free from the hypertensive crisis, the so-called cheese effect. Therefore, selective MAO-B inhibitors and RIMAs hold promise as safer alternatives to classical MAOIs. It is clear that much remains to be investigated with regard to the clinical pharmacology of MAOIs. It seems obvious that a greater understanding of the pharmacodynamics and pharmacokinetics of MAOIs could result in improved treatment of the patients in the future.
C02	`01`	`X`		`@0 002A25`
C02	`02`	`X`		`@0 002B03`
C02	`03`	`X`		`@0 002B17`
C03	`01`	`X`	`FRE`	`@0 Pharmacologie clinique @5 01`
C03	`01`	`X`	`ENG`	`@0 Clinical pharmacology @5 01`
C03	`01`	`X`	`SPA`	`@0 Farmacología clinica @5 01`
C03	`02`	`X`	`FRE`	`@0 IMAO @5 04`
C03	`02`	`X`	`ENG`	`@0 MAO inhibitor @5 04`
C03	`02`	`X`	`SPA`	`@0 IMAO @5 04`
C03	`03`	`X`	`FRE`	`@0 Toxicité @5 07`
C03	`03`	`X`	`ENG`	`@0 Toxicity @5 07`
C03	`03`	`X`	`SPA`	`@0 Toxicidad @5 07`
C03	`04`	`X`	`FRE`	`@0 Neurologie @5 11`
C03	`04`	`X`	`ENG`	`@0 Neurology @5 11`
C03	`04`	`X`	`SPA`	`@0 Neurología @5 11`
C03	`05`	`X`	`FRE`	`@0 Toxicologie @5 12`
C03	`05`	`X`	`ENG`	`@0 Toxicology @5 12`
C03	`05`	`X`	`SPA`	`@0 Toxicología @5 12`
N21				`@1 131`
N82				`@1 OTO`

Format Inist (serveur)

NO :	PASCAL 04-0190285 INIST
ET :	Clinical pharmacology of MAO inhibitors: Safety and future
AU :	YAMADA (Mitsuhiko); YASUHARA (Hajime); NICOTRA (A.); PARVEZ (S. H.); GLOVER (V.); SANDLER (M.); PARVEZ (S.); MINAMI (M.)
AF :	Department of Psychiatry, Showa University Karasuyama Hospital, 6-11-11 Kitakarasuyama/Setagaya, Tokyo 157-8577/Japon (1 aut.); Department of Pharmacology, Showa University School of Medicine/Tokyo 142-8555/Japon (2 aut.); Dept. Animal and Human Biology, University of Rome I, Viale dell'Università 32/00198 Rome/Italie (1 aut.); Institut Alfred Fressard of Neuroscience, Bât5 Parc Chateau, CNRS/91190 Gif sur Yvette/France (2 aut., 5 aut.); Institute of Reproductive and Developmental Biology, Imperial College London, Hammersmith Campus, Du Cane Road/London, W12 ONN/Royaume-Uni (3 aut., 4 aut.); The Research Institute of Personalized Health, Health Sciences University of Hokkaido/061-0293 Ishikari-Tobetsu/Japon (6 aut.)
DT :	Publication en série; Niveau analytique
SO :	Neurotoxicology : (Park Forest South); ISSN 0161-813X; Etats-Unis; Da. 2004; Vol. 25; No. 1-2; Pp. 215-221; Bibl. 1 p.1/4
LA :	Anglais
EA :	In this article, we review the clinical pharmacology of monoamine oxidase inhibitors (MAOIs). Now, MAOIs are used for the treatment of depressive disorders, anxiety disorders, Parkinson's disease, and Alzheimer's disease. The selective monoamine oxidase-B inhibitor selegiline and the selective and reversible inhibitor of monoamine oxidase-A (RIMA) moclobemide are free from the hypertensive crisis, the so-called cheese effect. Therefore, selective MAO-B inhibitors and RIMAs hold promise as safer alternatives to classical MAOIs. It is clear that much remains to be investigated with regard to the clinical pharmacology of MAOIs. It seems obvious that a greater understanding of the pharmacodynamics and pharmacokinetics of MAOIs could result in improved treatment of the patients in the future.
CC :	002A25; 002B03; 002B17
FD :	Pharmacologie clinique; IMAO; Toxicité; Neurologie; Toxicologie
ED :	Clinical pharmacology; MAO inhibitor; Toxicity; Neurology; Toxicology
SD :	Farmacología clinica; IMAO; Toxicidad; Neurología; Toxicología
LO :	INIST-18397.354000119285470220
ID :	04-0190285

Links to Exploration step

Pascal:04-0190285

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Clinical pharmacology of MAO inhibitors: Safety and future</title>
<author><name sortKey="Yamada, Mitsuhiko" sort="Yamada, Mitsuhiko" uniqKey="Yamada M" first="Mitsuhiko" last="Yamada">Mitsuhiko Yamada</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Psychiatry, Showa University Karasuyama Hospital, 6-11-11 Kitakarasuyama</s1>
<s2>Setagaya, Tokyo 157-8577</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Yasuhara, Hajime" sort="Yasuhara, Hajime" uniqKey="Yasuhara H" first="Hajime" last="Yasuhara">Hajime Yasuhara</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Pharmacology, Showa University School of Medicine</s1>
<s2>Tokyo 142-8555</s2>
<s3>JPN</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">04-0190285</idno>
<date when="2004">2004</date>
<idno type="stanalyst">PASCAL 04-0190285 INIST</idno>
<idno type="RBID">Pascal:04-0190285</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000E47</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Clinical pharmacology of MAO inhibitors: Safety and future</title>
<author><name sortKey="Yamada, Mitsuhiko" sort="Yamada, Mitsuhiko" uniqKey="Yamada M" first="Mitsuhiko" last="Yamada">Mitsuhiko Yamada</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Psychiatry, Showa University Karasuyama Hospital, 6-11-11 Kitakarasuyama</s1>
<s2>Setagaya, Tokyo 157-8577</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Yasuhara, Hajime" sort="Yasuhara, Hajime" uniqKey="Yasuhara H" first="Hajime" last="Yasuhara">Hajime Yasuhara</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Pharmacology, Showa University School of Medicine</s1>
<s2>Tokyo 142-8555</s2>
<s3>JPN</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Neurotoxicology : (Park Forest South)</title>
<title level="j" type="abbreviated">Neurotoxicology : (Park Forest South)</title>
<idno type="ISSN">0161-813X</idno>
<imprint><date when="2004">2004</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Neurotoxicology : (Park Forest South)</title>
<title level="j" type="abbreviated">Neurotoxicology : (Park Forest South)</title>
<idno type="ISSN">0161-813X</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Clinical pharmacology</term>
<term>MAO inhibitor</term>
<term>Neurology</term>
<term>Toxicity</term>
<term>Toxicology</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Pharmacologie clinique</term>
<term>IMAO</term>
<term>Toxicité</term>
<term>Neurologie</term>
<term>Toxicologie</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">In this article, we review the clinical pharmacology of monoamine oxidase inhibitors (MAOIs). Now, MAOIs are used for the treatment of depressive disorders, anxiety disorders, Parkinson's disease, and Alzheimer's disease. The selective monoamine oxidase-B inhibitor selegiline and the selective and reversible inhibitor of monoamine oxidase-A (RIMA) moclobemide are free from the hypertensive crisis, the so-called cheese effect. Therefore, selective MAO-B inhibitors and RIMAs hold promise as safer alternatives to classical MAOIs. It is clear that much remains to be investigated with regard to the clinical pharmacology of MAOIs. It seems obvious that a greater understanding of the pharmacodynamics and pharmacokinetics of MAOIs could result in improved treatment of the patients in the future.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0161-813X</s0>
</fA01>
<fA03 i2="1"><s0>Neurotoxicology : (Park Forest South)</s0>
</fA03>
<fA05><s2>25</s2>
</fA05>
<fA06><s2>1-2</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Clinical pharmacology of MAO inhibitors: Safety and future</s1>
</fA08>
<fA09 i1="01" i2="1" l="ENG"><s1>Monoamine Oxidases: Molecular, Pharmacological and Neurotoxicological Aspects. A Tribute to Prof. Merton Sandler</s1>
</fA09>
<fA11 i1="01" i2="1"><s1>YAMADA (Mitsuhiko)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>YASUHARA (Hajime)</s1>
</fA11>
<fA12 i1="01" i2="1"><s1>NICOTRA (A.)</s1>
<s9>ed.</s9>
</fA12>
<fA12 i1="02" i2="1"><s1>PARVEZ (S. H.)</s1>
<s9>ed.</s9>
</fA12>
<fA12 i1="03" i2="1"><s1>GLOVER (V.)</s1>
<s9>ed.</s9>
</fA12>
<fA12 i1="04" i2="1"><s1>SANDLER (M.)</s1>
<s9>ed.</s9>
</fA12>
<fA12 i1="05" i2="1"><s1>PARVEZ (S.)</s1>
<s9>ed.</s9>
</fA12>
<fA12 i1="06" i2="1"><s1>MINAMI (M.)</s1>
<s9>ed.</s9>
</fA12>
<fA14 i1="01"><s1>Department of Psychiatry, Showa University Karasuyama Hospital, 6-11-11 Kitakarasuyama</s1>
<s2>Setagaya, Tokyo 157-8577</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Department of Pharmacology, Showa University School of Medicine</s1>
<s2>Tokyo 142-8555</s2>
<s3>JPN</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA15 i1="01"><s1>Dept. Animal and Human Biology, University of Rome I, Viale dell'Università 32</s1>
<s2>00198 Rome</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
</fA15>
<fA15 i1="02"><s1>Institut Alfred Fressard of Neuroscience, Bât5 Parc Chateau, CNRS</s1>
<s2>91190 Gif sur Yvette</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
</fA15>
<fA15 i1="03"><s1>Institute of Reproductive and Developmental Biology, Imperial College London, Hammersmith Campus, Du Cane Road</s1>
<s2>London, W12 ONN</s2>
<s3>GBR</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</fA15>
<fA15 i1="04"><s1>The Research Institute of Personalized Health, Health Sciences University of Hokkaido</s1>
<s2>061-0293 Ishikari-Tobetsu</s2>
<s3>JPN</s3>
<sZ>6 aut.</sZ>
</fA15>
<fA20><s1>215-221</s1>
</fA20>
<fA21><s1>2004</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>18397</s2>
<s5>354000119285470220</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2004 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>1 p.1/4</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>04-0190285</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Neurotoxicology : (Park Forest South)</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>In this article, we review the clinical pharmacology of monoamine oxidase inhibitors (MAOIs). Now, MAOIs are used for the treatment of depressive disorders, anxiety disorders, Parkinson's disease, and Alzheimer's disease. The selective monoamine oxidase-B inhibitor selegiline and the selective and reversible inhibitor of monoamine oxidase-A (RIMA) moclobemide are free from the hypertensive crisis, the so-called cheese effect. Therefore, selective MAO-B inhibitors and RIMAs hold promise as safer alternatives to classical MAOIs. It is clear that much remains to be investigated with regard to the clinical pharmacology of MAOIs. It seems obvious that a greater understanding of the pharmacodynamics and pharmacokinetics of MAOIs could result in improved treatment of the patients in the future.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002A25</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B03</s0>
</fC02>
<fC02 i1="03" i2="X"><s0>002B17</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Pharmacologie clinique</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Clinical pharmacology</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Farmacología clinica</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>IMAO</s0>
<s5>04</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>MAO inhibitor</s0>
<s5>04</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>IMAO</s0>
<s5>04</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Toxicité</s0>
<s5>07</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Toxicity</s0>
<s5>07</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Toxicidad</s0>
<s5>07</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Neurologie</s0>
<s5>11</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Neurology</s0>
<s5>11</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Neurología</s0>
<s5>11</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Toxicologie</s0>
<s5>12</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Toxicology</s0>
<s5>12</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Toxicología</s0>
<s5>12</s5>
</fC03>
<fN21><s1>131</s1>
</fN21>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 04-0190285 INIST</NO>
<ET>Clinical pharmacology of MAO inhibitors: Safety and future</ET>
<AU>YAMADA (Mitsuhiko); YASUHARA (Hajime); NICOTRA (A.); PARVEZ (S. H.); GLOVER (V.); SANDLER (M.); PARVEZ (S.); MINAMI (M.)</AU>
<AF>Department of Psychiatry, Showa University Karasuyama Hospital, 6-11-11 Kitakarasuyama/Setagaya, Tokyo 157-8577/Japon (1 aut.); Department of Pharmacology, Showa University School of Medicine/Tokyo 142-8555/Japon (2 aut.); Dept. Animal and Human Biology, University of Rome I, Viale dell'Università 32/00198 Rome/Italie (1 aut.); Institut Alfred Fressard of Neuroscience, Bât5 Parc Chateau, CNRS/91190 Gif sur Yvette/France (2 aut., 5 aut.); Institute of Reproductive and Developmental Biology, Imperial College London, Hammersmith Campus, Du Cane Road/London, W12 ONN/Royaume-Uni (3 aut., 4 aut.); The Research Institute of Personalized Health, Health Sciences University of Hokkaido/061-0293 Ishikari-Tobetsu/Japon (6 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Neurotoxicology : (Park Forest South); ISSN 0161-813X; Etats-Unis; Da. 2004; Vol. 25; No. 1-2; Pp. 215-221; Bibl. 1 p.1/4</SO>
<LA>Anglais</LA>
<EA>In this article, we review the clinical pharmacology of monoamine oxidase inhibitors (MAOIs). Now, MAOIs are used for the treatment of depressive disorders, anxiety disorders, Parkinson's disease, and Alzheimer's disease. The selective monoamine oxidase-B inhibitor selegiline and the selective and reversible inhibitor of monoamine oxidase-A (RIMA) moclobemide are free from the hypertensive crisis, the so-called cheese effect. Therefore, selective MAO-B inhibitors and RIMAs hold promise as safer alternatives to classical MAOIs. It is clear that much remains to be investigated with regard to the clinical pharmacology of MAOIs. It seems obvious that a greater understanding of the pharmacodynamics and pharmacokinetics of MAOIs could result in improved treatment of the patients in the future.</EA>
<CC>002A25; 002B03; 002B17</CC>
<FD>Pharmacologie clinique; IMAO; Toxicité; Neurologie; Toxicologie</FD>
<ED>Clinical pharmacology; MAO inhibitor; Toxicity; Neurology; Toxicology</ED>
<SD>Farmacología clinica; IMAO; Toxicidad; Neurología; Toxicología</SD>
<LO>INIST-18397.354000119285470220</LO>
<ID>04-0190285</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000E47 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000E47 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    ParkinsonFranceV1
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:04-0190285
   |texte=   Clinical pharmacology of MAO inhibitors: Safety and future
}}

This area was generated with Dilib version V0.6.29.
Data generation: Wed May 17 19:46:39 2017. Site generation: Mon Mar 4 15:48:15 2024

	La maladie de Parkinson en France (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

La maladie de Parkinson en France (serveur d'exploration)

Clinical pharmacology of MAO inhibitors: Safety and future

Clinical pharmacology of MAO inhibitors: Safety and future

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri